*Some Market data delayed by 15 mins.

Kiora Pharmaceuticals, Inc. Common Stock

Symbol: KPRX (NASDAQ)
2.54 ▲ (2.83%) 0.070

Company Description:
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Key Stats
  • Today's Open: $2.49
  • Today's High: $2.54
  • Today's Low: $2.22
  • Today's Volume: 93.02K
  • Yesterday Close: $2.47
  • Yesterday High: $2.62
  • Yesterday Low: $2.44
  • Yesterday Volume: 124.63K
  • Last Min Volume: 0
  • Last Min High: $2.54
  • Last Min Low: $2.493
  • Last Min VWAP: $0
Company Profile
  • Name: Kiora Pharmaceuticals, Inc. Common Stock
  • Website: https://www.kiorapharma.com
  • Listed Date: 2015-02-13
  • Location: ENCINITAS, CA
  • Market Status: Active
  • CIK Number: 0001372514
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $8.48M
  • Round Lot: 100
  • Outstanding Shares: 3.43M
  • Asset Type: CS
RECENT FILINGS FOR KPRX
Filing Date Filing Type Format
2025-09-19 EFFECT View
2025-09-15 S-3 View
2025-08-14 SCHEDULE 13G/A View
2025-08-14 SCHEDULE 13G View
2025-08-13 SCHEDULE 13G/A View
2025-08-13 8-K View
2025-08-08 8-K View
2025-08-08 10-Q View
2025-07-01 UPLOAD View
2025-06-20 CORRESP View
2025-06-10 UPLOAD View
2025-06-04 8-K View
2025-06-03 8-K View
2025-05-09 8-K View
2025-05-09 10-Q View
2025-04-30 DEF 14A View
2025-04-02 4 View
2025-04-02 4 View
2025-04-02 4 View
2025-04-02 4 View
Latest News on KPRX

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.